PARP Inhibitors for Cancer Therapy

Ken Y. Lin; W. Lee Kraus

doi:10.1016/j.cell.2017.03.034

PARP Inhibitors for Cancer Therapy

Ken Y. Lin, W. Lee Kraus

Research output: Contribution to journal › Short survey › peer-review

78 Scopus citations

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

Original language	English (US)
Pages (from-to)	183
Number of pages	1
Journal	Cell
Volume	169
Issue number	2
DOIs	https://doi.org/10.1016/j.cell.2017.03.034
State	Published - Apr 6 2017
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2017.03.034

Cite this

@article{b4a8e0870cc84fa188833ca340fb281a,

title = "PARP Inhibitors for Cancer Therapy",

abstract = "Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.",

author = "Lin, {Ken Y.} and Kraus, {W. Lee}",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

month = apr,

day = "6",

doi = "10.1016/j.cell.2017.03.034",

language = "English (US)",

volume = "169",

pages = "183",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - PARP Inhibitors for Cancer Therapy

AU - Lin, Ken Y.

AU - Kraus, W. Lee

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

AB - Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

UR - http://www.scopus.com/inward/record.url?scp=85016957959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016957959&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.03.034

DO - 10.1016/j.cell.2017.03.034

M3 - Short survey

C2 - 28388401

AN - SCOPUS:85016957959

SN - 0092-8674

VL - 169

SP - 183

JO - Cell

JF - Cell

IS - 2

ER -

PARP Inhibitors for Cancer Therapy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this